117 related articles for article (PubMed ID: 23952019)
1. CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardin L; Calzà L; Norris D; Cicirello H; Casula D; Imbimbo B
Curr Alzheimer Res; 2013 Aug; ():. PubMed ID: 23952019
[TBL] [Abstract][Full Text] [Related]
2. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calza L; Norris D; Cicirello H; Casula D; Imbimbo BP
Curr Alzheimer Res; 2013 Sep; 10(7):742-53. PubMed ID: 23968157
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.
Imbimbo BP; Frigerio E; Breda M; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calzà L; Norris D; Casula D; Shenouda M
Alzheimer Dis Assoc Disord; 2013; 27(3):278-86. PubMed ID: 22922591
[TBL] [Abstract][Full Text] [Related]
4. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
[TBL] [Abstract][Full Text] [Related]
7. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Porrini V; Lanzillotta A; Branca C; Benarese M; Parrella E; Lorenzini L; Calzà L; Flaibani R; Spano PF; Imbimbo BP; Pizzi M
Neuroscience; 2015 Aug; 302():112-20. PubMed ID: 25450955
[TBL] [Abstract][Full Text] [Related]
8. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study.
Bourdès V; Dogterom P; Aleman A; Parmantier P; Colas D; Lemarchant S; Marie S; Chou T; Abd-Elaziz K; Godfrin Y
Neurol Ther; 2022 Sep; 11(3):1353-1374. PubMed ID: 35779189
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
13. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
15. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
17. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
Ringman JM; Frautschy SA; Teng E; Begum AN; Bardens J; Beigi M; Gylys KH; Badmaev V; Heath DD; Apostolova LG; Porter V; Vanek Z; Marshall GA; Hellemann G; Sugar C; Masterman DL; Montine TJ; Cummings JL; Cole GM
Alzheimers Res Ther; 2012; 4(5):43. PubMed ID: 23107780
[TBL] [Abstract][Full Text] [Related]
18. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
19. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Dyker AG; Lees KR
Stroke; 1999 Sep; 30(9):1796-801. PubMed ID: 10471426
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
